Metabasis Therapeutics (MBRX): Another Biopharma Microcap Implodes
July 17, 2007 by Douglas A. McIntyreMetabasis Therapeutics (MBRX) is off 56% to $3 after its diabetes drug candidate CS-917 failed to significantly lower blood sugar in a mid-stage trial. The company has traded as high as $8.64 in the last year.
It is another example of the "one trick pony" microcap biopharma’s that have nothing to offer but a one product trial. In the last quarter, the company lost over $9 million on revenue of $3.4 million. It loss has been about the level for each of the last four quarters. Add to this that the company had a market cap of $250 million within the last year.
Amazing risk.
Douglas A. McIntyre
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.